Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (191)	11/20/1997 3:51:00 AM
From: flickerful	Respond to of 756

with two eyes of coal? you're right... that's him alright.<eom>

To: 5,17,37,5,101,... who wrote (191)	11/20/1997 6:06:00 PM
From: flickerful	Read Replies (1) \| Respond to of 756

NEWS... Wednesday November 19, 11:16 am Eastern Time Company Press Release SOURCE: IVAX Corporation IVAX Receives World's First Approval for Beclomethasone in Non-CFC Inhaler MIAMI, Nov. 19 /PRNewswire/ -- IVAX Corporation (Amex: IVX - news) today announced that its United Kingdom subsidiary, Norton Healthcare Limited, has received marketing clearance in France and Ireland for the world's first chlorofluorocarbon (CFC)-free metered-dose inhaler (MDI) for beclomethasone dipropionate, a corticosteroid indicated for the control of symptoms associated with chronic bronchial asthma. This environmentally friendly MDI uses a hydrofluoroalkane (HFA) in place of a CFC propellant; CFCs contribute to ozone depletion and are the subject of a treaty calling for their eventual ban. Norton Healthcare has applications for this product pending at the Medicine Control Agency in the United Kingdom and expects to file additional applications in other world markets. ''We are developing other respiratory products using CFC-free propellants and our goal is to have our line of MDI medications in CFC-free propelled inhalers ahead of the worldwide ban on CFC propelled asthma inhalers,'' said David R. Bethune, IVAX President and Chief Operating Officer. Norton Healthcare intends to commercialize the HFA beclomethasone dipropionate MDI in Ireland directly, and is currently negotiating with a marketing partner to distribute the product in France. The use of HFAs in pharmaceutical aerosols is the subject of various patents held by third parties throughout the world. In the United Kingdom, Norton Healthcare successfully invalidated certain patents held by 3M Company and 3M has filed an appeal which is pending. Norton Healthcare intends to challenge other patents which purport to cover the use of HFAs in pharmaceutical aerosols. IVAX Corporation, headquartered in Miami, Florida, is a holding company with core subsidiaries engaged primarily in the research, development, manufacture and marketing of generic and branded pharmaceuticals. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties which may affect the company's business and prospects, including the risk that IVAX may not successfully commercialize its HFA inhaler due to, among other things, patents held by third parties or the failure to contract with a suitable marketing partner, and certain economic, competitive, governmental, technological and other factors discussed in IVAX's filings with the Securities and Exchange Commission. SOURCE: IVAX Corporation ------------------------------------------------------------------------

To: 5,17,37,5,101,... who wrote (191)	11/20/1997 8:58:00 PM
From: flickerful	Respond to of 756

worth noting....Wednesday November 19, 11:08 am Eastern Time Company Press Release SOURCE: Barr Laboratories, Inc. Massachusetts Rejects DuPont Merck Petition to Block Barr's Generic Coumadin; Science Triumphs Over DuPont Merck's Anti-Consumer, Anti-Competitive Efforts POMONA, N.Y., Nov. 19 /PRNewswire/ -- Barr Laboratories, Inc. (Amex: BRL - news) today hailed the decision by the Massachusetts Drug Formulary Commission on Tuesday evening to reject a petition by DuPont Merck that would have blocked substitution of Barr's Warfarin Sodium, the generic equivalent of DuPont Merck's Coumadin(R) anti-coagulant. The unanimous vote of the Commission members followed testimony by Roger L. Williams, M.D., Deputy Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, and a presentation by Joel Neutel, M.D., Director of Research, Orange County Heart Institute, who recently completed an independent clinical study on the interchangeability of Barr's generic Warfarin Sodium with Coumadin. Dr. Williams testified about the rigorous standards that generic products must meet to receive FDA approval, and told the panel that generic NTI drugs approved by FDA can be substituted with the full expectation by the patient and physician that they will have the same clinical effect and safety profile as the innovator drug. Dr. Neutel explained that his clinical findings demonstrated that Coumadin and Barr's Warfarin Sodium products have equivalent safety and efficacy and that no additional blood tests are required when the products are interchanged. Full details of this clinical trial, which was announced earlier this week, will be submitted for publication in early 1998. ''In Massachusetts, science has spoken to defeat the anti-consumer and anti-competitive actions of DuPont Merck,'' said Bruce L. Downey, Barr's Chairman, President and CEO. ''When presented with clinical and scientific evidence, the Massachusetts scientific body responsible for reviewing drug products and determining if generic substitution is permitted has voted unanimously in favor of preserving consumer access to safe, effective and more affordable generic medicines. This victory confirms the baseless nature of DuPont Merck's monopolistic attempt to have states implement legislation and regulations to block substitution of our generic version of Coumadin.'' Since January of 1997, DuPont Merck has been engaged in an effort to block competition for their Coumadin product, which has been off patent since 1962. In the past ten years, DuPont Merck has increased the price of this increasingly popular therapy by more than 400%. Barr's Warfarin Sodium product entered the market in late July, and nearly one-quarter of a million prescriptions have been filled since launch. The Company is supporting Warfarin Sodium with an extensive promotional and educational program that includes materials targeted to the physician, pharmacist and patient, as well as trade advertising, direct mail components, and a toll-free number: 1-888-WARFARIN (927-3274) for patients and health care providers. Barr Laboratories, Inc. is a leading independent developer, manufacturer, and marketer of high quality generic pharmaceuticals. SOURCE: Barr Laboratories, Inc. ------------------------------------------------------------------------